MedTech Dive June 7, 2022
When Dexcom quashed reports last week that it was in talks to buy Insulet, one key question still remained for the company: When would the G7 continuous glucose monitoring system be cleared for the U.S. market?
J.P. Morgan has touted the product as one of the medical device industry’s biggest launches of the year and Dexcom executives said that a decision could come in June around the American Diabetes Association’s annual conference.
Still, as the ADA conference wraps up this week, there still hasn’t been a decision from the Food and Drug Administration and Dexcom currently doesn’t have a timeline.
“We’re not there yet. We have more work to do,” CEO Kevin Sayer said in an interview. “I don’t have...
Today's Sponsors
Today's Sponsor